Search Results
Mar 25, 2026, 17:30 ET Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
In December 2025, Atossa announced that the U.S. Food and Drug Administration ("FDA") granted Rare Pediatric Disease ("RPD") designation to (Z)-endoxifen for the treatment of DMD. RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect
More news about: Atossa Therapeutics Inc
Mar 11, 2026, 10:00 ET Verve Medical Treats First Patient in Landmark U.S. Pilot Trial for Uncontrolled Hypertension, Advancing Momentum from Breakthrough TUSK Results
understanding of blood pressure regulation and its relationship with renal function. The RPD Pilot trial is enrolling 60 patients across 10 U.S. clinical sites, with participants randomized to receive either RPD therapy or a sham procedure to ensure rigor and objectivity. "Based on prior
More news about: Verve Medical
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
with DM1. ATX-01 has received Orphan Drug Designation for ATX-01 in DM1 from the US FDA and European authorities, as well as Rare Pediatric Disease (RPD) Designation from the FDA. About ARTHEx Biotech ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed
More news about: ARTHEx Biotech
Feb 05, 2026, 08:30 ET Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a
More news about: Atossa Therapeutics Inc
Jan 26, 2026, 08:30 ET Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II
The FDA grants RPD designation for serious or life-threatening diseases that primarily affect children 18 years old or younger and affect fewer than 200,000 people nationwide. RPD designation allows recipient companies, upon approval of their designated
More news about: Immusoft
Jan 22, 2026, 10:38 ET The Security Reset: Why Protecting Infrastructure is Driving a New Growth Cycle
Encryption Corp. (QSE) (CSE: QSE) (OTCQB: QSEGF) (FSE: VN8), Parsons Corporation (NYSE: PSN), F5 (NASDAQ: FFIV), Rapid7 (NASDAQ: RPD), and Impinj (NASDAQ: PI).
More news about: USA News Group
Jan 08, 2026, 12:40 ET The $190B Data Lockdown: Why 'Sovereign Tech' is the Next Massive Wealth Transfer
QSEGF) (FSE: VN8), Elastic (NYSE: ESTC), SentinelOne, Inc. (NYSE: S), Nutanix (NASDAQ: NTNX), and Rapid7, Inc. (NASDAQ: RPD).
More news about: Equity Insider
Dec 11, 2025, 08:00 ET Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a
More news about: Atossa Therapeutics Inc
Dec 04, 2025, 12:54 ET America's Rare Children Need Congress to Act: NORD Urges Swift Reauthorization of Proven Rare Pediatric Disease Voucher Program
/PRNewswire/ -- The National Organization for Rare Disorders (NORD®) today urged Congress to reauthorize the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program by year-end, warning that continued delay threatens the future of innovation for children with rare diseases.
More news about: National Organization for Rare Disorders (NORD®)
Dec 01, 2025, 08:00 ET Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
carcinoma (LG-UTUC, SURF303) and potentially future mUC clinical trials. The FDA has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to dabogratinib for the treatment of achondroplasia.Please visit the
More news about: Tyra Biosciences
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
urothelial carcinoma (SURF303) and potentially future mUC clinical trials. The FDA has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to dabogratinib for the treatment of achondroplasia. BEACH301 is a Phase 2, multicenter, open-label, dose-escalation/dose-expansion
More news about: Tyra Biosciences
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
DM1. ATX-01 has received Orphan Drug Designation for ATX-01 in DM1 from the US FDA and European authorities, as well as Rare Pediatric Disease (RPD) Designation from the FDA. About ARTHEx Biotech ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed
More news about: ARTHEx Biotech
Aug 21, 2025, 08:00 ET Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
and potentially future mUC studies. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to dabogratinib for the treatment of achondroplasia. Please visit the
More news about: Tyra Biosciences
Aug 06, 2025, 17:46 ET Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight
clinical evaluation for advanced urothelial carcinoma, and in February 2024, it received the FDA's Rare Pediatric Disease (RPD) designation. The anticipated launch of these emerging therapies are poised to transform the urothelial carcinoma market landscape in the coming
More news about: DelveInsight Business Research, LLP
Jul 08, 2025, 08:00 ET Harmonic Sets DOCSIS 4.0 Record with 14 Gbps Downstream Speed at CableLabs Interoperability Event
Jones, principal architect at CableLabs. "These intensive sessions — which involve numerous upgrade cycles — are instrumental to advancing modem, RPD and Core interoperability and ensuring readiness for certification. The recent achievement of 14 Gbps downstream DOCSIS throughput across a multi-vendor
More news about: Harmonic Inc.
May 12, 2025, 17:34 ET HERTZ REPORTS SIGNIFICANT PROGRESS TOWARDS KEY MILESTONES FOR FIRST QUARTER 2025
comparisons with other participants in the vehicle rental industry. Total Revenue Per Transaction Day ("Total RPD"or "RPD"; also referred to as "pricing") Total RPD represents revenue generated per transaction day, excluding the impact of foreign currency exchange rates so as not to
More news about: Hertz Global Holdings, Inc.
May 07, 2025, 09:07 ET FDA Grants Orphan Drug & Rare Pediatric Disease Designations to Infinant Health for NEC
approved for marketing, market exclusivity. The RPDD grants the company a priority review voucher (PRV), provided approval for INF108 occurs before the RPD program sunsets. If Congress does not renew the program, it will sunset in September 2026. A PRV can be used to ensure
More news about: Infinant Health